In total, patients were treated with Kogenate or Helixate on 4267 days, Kogenate Bayer on 378 days, Recombinate on 1639 days, and Refacto on 2209 days. Overall, plasma-derived products were given on 4415 days; fresh frozen plasma on 10 days; Aafact on 41 days; Alphanate on 18 days; Alpha-Profilate on 157 days; Amofil on 50 days, Beriate on 1201 days; BPL 8Y on 302 days; Criostat on 11 days; Emoclot on 163 days; a factor VIII product from a local blood bank (Dutch) on 49 days; FVIII SD (Belgium) on 100 days; Fanhdi on 45 days; factor VIII-LFB on 2 days; Haemate P on 479 days; Hemofil-M on 206 days; Hemofil T on 98 days; Hemoctin on 50 days; Immunate on 152 days; Innovate on 129 days; Koate on 181 days; Monoclate on 323 days; Octonativ M on 457 days; Replenate on 200 days; and Uman-Cry on 1 day.

The CANAL Study group consists of the following investigators (with number of patients): C. Altisent, Unidad de Hemofilia, Hospital de la Vall d’Hebron, Barcelona, Spain (18); G. Auerswald, Comprehensive Care Center for Thrombosis and Haemostasis, Klinikum Bremen-Mitte, Professor Hess Children’s Hospital, Bremen, Germany (26); H. Chambost, Service de Pediattrie et d’Hematologie Pediatrique, Centre Regional de Traitement de l’Hemophilie, CHU Hopital d’Enfants La Timone, Universite de la Mediterranee, Marseille, France (9); A. R. Cid and S. Haya, Unidad de Coagulopatias Congenitas, Hospital Universitario La Fe, Valencia, Spain (20); C. Escuriola Ettinghausen and W. Kreuz, Department of Paediatric Haematology, Oncology, and Haemostaseology, University Children’s Hospital, Frankfurt, Germany (41); Ch. v Geet and K. Peerlinck, Department of Pediatrics (Hematology), Haemophilia Treatment Center, University Hospital Gasthuisberg, Leuven, Belgium (12); S. C. Gouw, H. M. van den Berg, and J. G. van der Bom, Van Creveldkliniek, University Medical Center Utrecht, Utrecht, the Netherlands (37); R. Liesner, Department of Haematology & Oncology and Children’s Haemophilia Comprehensive Care Centre, Great Ormond Street Children’s Hospital & Institute of Child Health, London, United Kingdom (32); P. Petrini, Haemophilia Center, Karolinska Hospital, Stockholm, Sweden (30); G. Rivard, Centre d’Hemophilie, Sainte-Justine Hospital, Montreal, QC (16); E. Santagostino and M. E. Mancuso, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and Medical Specialties, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation and University of Milan, Milan, Italy (44); U. Tedgård, Department of Paediatrics, University of Lund, University Hospital, Malmö, Sweden (19); A. Villar and V. Jiménez Yuste, Hematology Department, Hospital Universitario La Paz, Madrid, Spain (33); T. T. Yee and C. A. Lee, Haemophilia Centre and Haemostasis Unit, The Royal Free Hospital, London, United Kingdom (29).